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We appreciate the interest by Chemla et al. in our study concern-
ing the analysis of pulmonary arterial reflection in the differential
diagnosis of chronic pulmonary thromboembolism (CPTE) and
primary pulmonary hypertension (PPH) (1). We used a fluid-filled
system to analyze arterial pressure waveform in previous studies
(1–3). If we had used a high-fidelity pressure transducer, the
recorded pressure waveform would have been more accurate. As a
high-fidelity catheter manometer is an expensive and intricate
system, high-fidelity measurement makes the analysis of reflection
waveform impractical in a clinical setting (4). To give the analysis
of pulmonary arterial reflection the clinical implications, we
measured inflection point using a fluid-filled recording system and
examined whether the inflection time was correctly defined. To
quantify the artery reflection, we used the augmentation index and
inflection time (1,2). Both the augmentation index and the
inflection time using a fluid-filled recording system were reliable
and unchanged by repeated measurements. The fact that we could
differentiate CPTE from PPH using the fluid-filled system should
be interpreted not as a weakness but as a strength of the study
(1,2).
Many workers have investigated the analysis of pulmonary
arterial reflection, and with controversial results (1,2). Main factors
contributing to this diversity include: 1) the effect of different
ethnic groups; 2) the effect of different measuring systems; and 3)
the effects on aging, the treatments and vasodilator severity of
pulmonary hypertension. Body mass index in the general Japanese
population is smaller than in Europeans and Americans. Thus, it
is natural that our results using fluid-filled catheters in Japanese
subjects are inconsistent with the results using high-fidelity cath-
eters in European subjects, to greater or lesser degree. Further-
more, the effects on aging, the treatments and vasodilator severity
of pulmonary hypertension modify pulmonary arterial reflection.
Comparison of our study with the study of Chemla et al. produces
controversial results without adjustment for these factors.
In conclusion, measurement of pulmonary artery pressure by
fluid-filled catheters is an inexpensive and simple procedure
compared to measurement by high-fidelity catheter. As analysis of
pulmonary artery reflection added to pulsatility of pulmonary
artery pressure waveform can help in differentiating between
CPTE and PPH, measurement of pulmonary reflection waveform
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Scopolamine?
On page 748 of the Kop et al. article (JACC 2001;38:742–9),
shouldn’t the third line from the end of the manuscript contain the
word “pilocarpine” or “physostigmine” instead of “scopolamine?”
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We thank the author for his interesting comment. Cumulating
evidence indicates that vagomimetic agents enhance measures of
cardiac parasympathetic activation, such as heart rate variability
(HRV) (1,2). Compared to other agents affecting parasympathetic
function, scopolamine has been most widely investigated in pa-
tients with documented coronary artery disease. In postmyocardial
infarction patients, scopolamine increases HRV and baroreceptor
reflex sensitivity (3,4). Transdermal scopolamine is also reported to
reduce ambulatory ischemia and ischemic threshold during exer-
cise testing in patients with severe coronary disease (5). Effects of
vagomimetic agents other than scopolamine have not been sys-
tematically studied in patients with established coronary disease.
Consistent with the comment above, a recent investigation by
Nobrega et al. (6) documented increased HRV in response to
pyridostigmine in healthy individuals. However, despite beneficial
effects on HRV and other indirect indices of autonomic nervous
system activity, vagomimetic agents do not necessarily reduce
arrhythmic vulnerability (1,2). Our data suggest that transient
pre-ischemic vagal withdrawal may be specific to ischemic events
triggered by mental stress (7). Further investigations are needed to
examine the potential benefits of vagomimetic agents in preventing
ischemia occurring at low cardiac demand thresholds, as com-
monly occurs with ischemia during ambulant monitoring and
during mental stress in the laboratory (8).
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